ArticleJournal of comparative effectiveness research2025

US cost-effectiveness analysis of apixaban compared with warfarin, dabigatran and rivaroxaban for nonvalvular atrial fibrillation, focusing on equal value of life years and health years in total.

Nipun Atreja et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.